


**Product Name** : GSK-J4  
**Cat. No.** : PC-21211  
**CAS No.** : 1373423-53-0  
**Molecular Formula** : C<sub>24</sub>H<sub>28</sub>ClN<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 453.97  
**Target** : Histone Demethylase  
**Solubility** : 10 mM in DMSO



## Biological Activity

GSK-J4 is a potent dual inhibitor of H3K27me<sub>3</sub>/me<sub>2</sub>-demethylases **JMJD3/KDM6B** and **UTX/KDM6A** with IC<sub>50</sub>s of 8.6 and 6.6 μM, respectively. GSK-J4 is a cell permeable prodrug of GSK-J1.

GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with IC<sub>50</sub> of 9 μM.

GSK-J4 prevents the JMJD3-induced loss of nuclear H3K27me<sub>3</sub> immunostaining in Flag-JMJD3-transfected HeLa cells.

GSK-J4 inhibits JMJD3 expression that is induced by TGF-β1, inhibits H3K4 demethylation at Xist, Nodal, and HoxC13 in female embryonic stem cells.

GSK-J4 attenuates the development of kidney disease in diabetic mice.

## References

Kruidenier L, et al. *Nature*. 2012 Aug 16;488(7411):404-8.

Majumder S, et al. *J Clin Invest*. 2018 Jan 2;128(1):483-499.

Donas C, et al. *J Autoimmun*. 2016 Dec;75:105-117.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com